Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of intravitreal JNJ-81201887 versus sham for geographic atrophy secondary to age-related macular degeneration
NL-OMON60288Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-81201887 in age-related macular degeneration (AMD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in square root geographic atrophy lesion area. Started Oct 2023; status: completed.
02
Drugs
JNJ-81201887
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON60288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60288.